pHLIP Inc.®was formed in 2015 to enable pH Low Insertion Peptide (pHLIP) targeted delivery of therapeutic, diagnostic, prophylactic, and research agents to cells in diseased, acidic tissues including cancers (breast, prostate, bladder, melanoma, lymphoma, pancreatic, lung, ovarian, brain) ischemic myocardium, inflammatory arthritis, and stroke. https://phlipinc.com/>
“pHLIP Inc.® acts as a molecular nanosyringe, inserting itself into the cell membrane and injecting compounds into cell,” said co-founder and president, Yana Reshetnyak. “The transported molecules can be therapeutic or toxic to the cell, depending on the intended outcome—for treating cancer, the idea is to cause cell death.” “Acidosis is a physiological marker of many diseases — and pHLIP® feels acidity,” said Reshetnyak. “Therefore, pHLIP® could also be used for monitoring of disease development and therapeutic outcomes in cancer, arthritis, ischemia, and stroke.”
pHLIP® technology will detect, target and treat acidic diseased tissue using selective insertion and folding of membrane peptides. The primary application market is oncology.
- Clinical tumor imaging with PET/SPECT-pHLIP® tracers on patients with breast and prostate tumors.
- Clinical application of fluorescent pHLIP® for Fluorescence-guided surgery and ex vivo imaging/histology.
- Therapeutic applications of pHLIP-based compounds including delivery of approved drugs, new potent polar toxins and gene-regulation agents, such as PNAs (Peptide Nucleic Acids).
URI technology, part of new cancer lead development program
Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting platform, recently announced CBX-12 (alphalex™-exatecan) as the new lead development program. CBX-12 is a conjugate that includes the highly potent topoisomerase I inhibitor exatecan linked to a pHLIP® peptide developed by URI Profs. Yana Reshetnyak, Oleg Andreev and Yale Prof. Dan Engelman.
The pHLIP® peptide enables preferential targeting of the exatecan, or other anti-cancer drugs to tumors, creating therapeutics with potentially far fewer side-effects, which would revolutionize the standard of care. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at the University of Rhode Island and Yale University, and is exclusively licensed to pHLIP, Inc.